Enhanced susceptibility to end-organ disease in the lupus-facilitating NZW mouse strain

被引:71
|
作者
Xie, C [1 ]
Zhou, XJ [1 ]
Liu, XB [1 ]
Mohan, C [1 ]
机构
[1] Univ Texas, SW Med Ctr, Dept Internal Med Rheumatol, Simmons Arthrit Res Ctr, Dallas, TX 75390 USA
来源
ARTHRITIS AND RHEUMATISM | 2003年 / 48卷 / 04期
关键词
D O I
10.1002/art.10887
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. Although the NZW mouse strain is phenotypically normal, fulminant lupus glomerulonephritis (GN) develops when NZW mice are bred to several other strains, such as NZB, BXSB, B6.Sle1, and B6.Yaa. Based on the observation that aging NZW mice exhibit histologic evidence of GN, we sought to test our hypothesis that NZW mice may be more susceptible to immune-mediated renal damage. Methods. NZW mice, as well as C57BL/6 (B6) and BALB/c control mice, were challenged with rabbit antiglomerular basement membrane nephrotoxic sera (NTS), to induce renal disease. The different mouse strains were monitored for the degree of clinical disease, renal pathology, chemokine profiles, and cellular infiltrates. Results. Although the NZW and control strains showed similar glomerular deposits of rabbit Ig and exhibited similar levels of anti-rabbit xenogeneic immune response, the NZW mice had significantly worse pathologic changes and disease. Compared with the control strains, the NTS-injected NZW mice demonstrated significantly increased proteinuria, elevated blood urea nitrogen levels, more severe histologic GN and tubulointerstitial nephritis, increased glomerular crescent formation with macrophage and neutrophil infiltrates, elevated expression of CC and CXC chemokines (monocyte chemoattractant protein 1, RANTES, KC), and significantly accelerated mortality. Importantly, these changes occurred within a few days after NTS administration. Finally, (B6 x NZW)F-1 mice were as susceptible as the NZW parents, which indicates dominant NZW contributions. Conclusion. Collectively, these findings support the notion that a lupus-facilitating genome may contribute to disease susceptibility by modulating the degree of immune-mediated end-organ damage. The availability of B6-based congenic strains bearing individual NZW-derived lupus susceptibility loci will permit future genetic dissection of end-organ susceptibility in murine lupus.
引用
收藏
页码:1080 / 1092
页数:13
相关论文
共 50 条
  • [41] Mineralocorticoid Receptor and Aldosterone-Related Biomarkers of End-Organ Damage in Cardiometabolic Disease
    Gorini, Stefania
    Marzolla, Vincenzo
    Mammi, Caterina
    Armani, Andrea
    Caprio, Massimiliano
    BIOMOLECULES, 2018, 8 (03)
  • [42] Infantile Congenital Mesoblastic Nephroma Leading to Multi-Systemic End-Organ Disease
    Grosinger, Liana
    Salik, Irim
    Mehta, Bhupen
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (10)
  • [43] Fatal histiocytic proliferative disorders in paediatric HIV infection with cytomegalovirus end-organ disease
    Nastouli, Eleni
    Carrol, Enitan
    Malone, Marian
    Riordan, Andrew
    Lyall, Hermione
    BRITISH JOURNAL OF HAEMATOLOGY, 2009, 146 (05) : 580 - 582
  • [44] GILZ Regulates the Expression of Pro-Inflammatory Cytokines and Protects Against End-Organ Damage in a Model of Lupus
    Nataraja, Champa
    Dankers, Wendy
    Flynn, Jacqueline
    Lee, Jacinta P. W.
    Zhu, Wendy
    Vincent, Fabien B.
    Gearing, Linden J.
    Ooi, Joshua
    Pervin, Mehnaz
    Cristofaro, Megan A.
    Sherlock, Rochelle
    Abul Hasnat, Md
    Harris, James
    Morand, Eric F.
    Jones, Sarah A.
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [45] Epitope Specificity and End-Organ Susceptibility Dictates Anti-Ro52 Mediated Salivary Gland Dysfunction
    Sroka, Magdalena
    Biswas, Indranil
    Shepherd, Brian
    Truong, Dat C.
    Bagavant, Harini
    Deshmukh, Umesh S.
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [46] Cytomegalovirus end-organ disease in immunocompromised critically ill patients: key concerns demanding attention
    Zhihui Zhang
    Junlu Sun
    Xuesong Liu
    Rong Zhang
    Yimin Li
    Xiaoqing Liu
    Critical Care, 28 (1):
  • [47] Ambulatory Hypertension in Pediatric Patients With Sickle Cell Disease and Its Association With End-Organ Damage
    Ranabothu, Saritha
    Hafeman, Michael
    Manwani, Deepa
    Reidy, Kimberly
    Morrone, Kerry
    Lorenzo, Josemiguel
    Tria, Barbara
    Kaskel, Frederick
    Mahgerefteh, Joseph
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2020, 12 (11)
  • [48] Lowering blood pressure in coronary heart disease -: Treating symptoms or preventing end-organ complications
    Böhm, M
    HERZ KREISLAUF, 2000, 32 (04): : 121 - 122
  • [49] Endothelin blockers and renal protection: a new strategy to prevent end-organ damage in cardiovascular disease?
    Rabelink, TJ
    Stroes, ESG
    Bouter, KP
    Morrison, P
    CARDIOVASCULAR RESEARCH, 1998, 39 (03) : 543 - 549
  • [50] End-organ ischemia in the absence of proximal obstructive arterial disease: Deja vu or jamais vu?
    Merz, C. Noel Bairey
    Cheng, Susan
    Raggi, Paolo
    Wei, Janet
    ATHEROSCLEROSIS, 2019, 287 : 162 - 164